Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $1.10 billion. The enterprise value is $1.15 billion.
Important Dates
The last earnings date was Wednesday, August 28, 2024, after market close.
Earnings Date | Aug 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.14 billion shares outstanding. The number of shares has increased by 26.87% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.14B |
Shares Change (YoY) | +26.87% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 848.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 13.66 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 195.54 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.25.
Current Ratio | 1.18 |
Quick Ratio | 1.14 |
Debt / Equity | 0.25 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2.81 |
Financial Efficiency
Return on equity (ROE) is -17.91% and return on invested capital (ROIC) is -5.95%.
Return on Equity (ROE) | -17.91% |
Return on Assets (ROA) | -5.41% |
Return on Capital (ROIC) | -5.95% |
Revenue Per Employee | $80,849 |
Profits Per Employee | -$1.20M |
Employee Count | 73 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | -191,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +337.71% in the last 52 weeks. The beta is 2.34, so Mesoblast's price volatility has been higher than the market average.
Beta (5Y) | 2.34 |
52-Week Price Change | +337.71% |
50-Day Moving Average | 8.81 |
200-Day Moving Average | 6.50 |
Relative Strength Index (RSI) | 56.31 |
Average Volume (20 Days) | 217,454 |
Short Selling Information
Short Interest | 1.39M |
Short Previous Month | 1.25M |
Short % of Shares Out | 1.58% |
Short % of Float | n/a |
Short Ratio (days to cover) | 6.69 |
Income Statement
In the last 12 months, Mesoblast had revenue of $5.90 million and -$87.96 million in losses. Loss per share was -$0.09.
Revenue | 5.90M |
Gross Profit | -35.17M |
Operating Income | -57.97M |
Pretax Income | -73.25M |
Net Income | -87.96M |
EBITDA | -56.08M |
EBIT | -57.97M |
Loss Per Share | -$0.09 |
Full Income Statement Balance Sheet
The company has $62.96 million in cash and $118.92 million in debt, giving a net cash position of -$55.96 million or -$0.05 per share.
Cash & Cash Equivalents | 62.96M |
Total Debt | 118.92M |
Net Cash | -55.96M |
Net Cash Per Share | -$0.05 |
Equity (Book Value) | 480.36M |
Book Value Per Share | 0.42 |
Working Capital | 13.22M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$48.46 million and capital expenditures -$271,000, giving a free cash flow of -$48.73 million.
Operating Cash Flow | -48.46M |
Capital Expenditures | -271,000 |
Free Cash Flow | -48.73M |
FCF Per Share | -$0.04 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -982.24% |
Pretax Margin | -1,493.51% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -818.02% |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -26.87% |
Shareholder Yield | -26.87% |
Earnings Yield | -8.00% |
FCF Yield | -4.43% |
Analyst Forecast
The average price target for Mesoblast is $11.50, which is 11.33% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.50 |
Price Target Difference | 11.33% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 168.66% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on January 10, 2024. It was a reverse split with a ratio of 0.5:1.
Last Split Date | Jan 10, 2024 |
Split Type | Reverse |
Split Ratio | 0.5:1 |
Scores
Mesoblast has an Altman Z-Score of -0.92 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.92 |
Piotroski F-Score | 3 |